Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Merck & Co. to buy neuroscience firm Caraway for $610 million
by Laura Howes
November 23, 2023
| A version of this story appeared in
Volume 101, Issue 39
Merck & Co. will acquire neuroscience-focused Caraway Therapeutics for up to $610 million in up-front and milestone payments. Merck has been a shareholder in the biotechnology firm since it launched in 2018 and will now purchase all outstanding shares in the company. In Caraway, Merck gets a pipeline of small-molecule candidates for treating neurodegenerative diseases. These drugs activate cellular recycling processes by modifying lysosomal function.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X